Results for tag: "Gilotrif"

Gilotrif (afatinib) is a type of targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that help cancer cells grow and divide. Gilotrif is approved for the treatment of patients with metastatic NSCLC whose tumors have certain types of epidermal growth factor receptor (EGFR) gene mutations. It is also approved for the first-line treatment of patients with metastatic NSCLC whose tumors have certain types of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. The Gilotrif market is a rapidly growing segment of the lung cancer drug market. It is driven by the increasing prevalence of NSCLC and the growing awareness of the importance of targeted therapies in treating the disease. The market is expected to continue to grow as more patients are diagnosed with NSCLC and as more targeted therapies become available. Some of the major companies in the Gilotrif market include Boehringer Ingelheim, AstraZeneca, Pfizer, and Merck. Show Less Read more